Vivos Therapeutics Inc Stock Price, News & Analysis

Vivos Therapeutics (NASDAQ: VVOS) has announced the 3rd-annual Breathing Wellness Conference, set for October 20-23, 2021, in Las Vegas. The event aims to educate dentists and doctors about innovative treatments for patients suffering from obstructive sleep apnea (OSA) and snoring. Key speakers will discuss the implications of OSA on chronic health issues like heart disease and the latest advancements in dentofacial sleep medicine. Vivos strives to provide non-invasive solutions, differentiating itself from traditional treatments like CPAP machines.

Vivos Therapeutics (NASDAQ: VVOS) has announced a strategic collaboration with Candid Care Co. to create a comprehensive solution for diagnosing and treating obstructive sleep apnea (OSA) and providing orthodontic treatment. The partnership aims to integrate Candid's CandidPro aligner system with Vivos' innovative Vivos System. This alliance will focus on shared marketing efforts, educational resources, and specialized training to enhance patient outcomes. Both companies expect to increase market penetration and drive revenue growth through this collaboration, tapping into existing dental and healthcare networks in the U.S. and Canada.

Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration with Candid Care to offer a comprehensive solution for obstructive sleep apnea (OSA) and orthodontic treatments. This partnership aims to combine Candid's clear aligners with Vivos' OSA treatment system, enhancing patient outcomes. The agreement includes joint marketing efforts, shared educational resources, and exploration of new research opportunities. The collaboration is expected to boost market penetration and revenue growth for both companies across North America.

Vivos Therapeutics (NASDAQ: VVOS) announced significant findings from a peer-reviewed study on its FDA-registered Vivos Guide, an intraoral device aimed at reducing pediatric tooth decay.

The study, led by Dr. Toshi Hart, demonstrated a 76.4% reduction in tooth decay risk at six months and 57.9% at twelve months for children using the device compared to a control group. The device encourages nasal breathing over mouth breathing, potentially increasing salivary factors that combat tooth decay.

Vivos Therapeutics (NASDAQ: VVOS) has established the Vivos Medical Consortium to enhance research in managing obstructive sleep apnea (OSA). Co-chaired by Dr. Clete Kushida from Stanford and Dr. Cecilia Wu from the University of Alberta, the consortium comprises specialists from various medical fields. The group's goal is to improve physician-dental collaboration and explore new applications for Vivos' OSA technology, which has shown promising results. Vivos aims to facilitate broader adoption of its innovative, non-invasive therapies for patients with OSA.

Vivos Therapeutics, Inc. (NASDAQ: VVOS), a company focused on innovative treatments for sleep-disordered breathing, will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 2:20 pm EST. The presentation will be led by Chairman Kirk Huntsman and CFO Brad Amman. Interested investors can register for a free spectator pass. Vivos offers non-surgical solutions for obstructive sleep apnea through its Vivos System, which has helped over 19,000 patients globally. A replay will be available on their website post-event.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced that CEO Kirk Huntsman will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 am EDT. Investors can register for the event and listen to the presentation via provided links. Vivos specializes in innovative treatments for mild-to-moderate obstructive sleep apnea (OSA), offering solutions like the Vivos System, which has aided over 19,000 patients worldwide. A replay of the presentation will be available on Vivos’ website post-event.

Vivos Therapeutics (NASDAQ: VVOS) has announced a partnership with Empower Sleep to enhance diagnostic and consultation services for obstructive sleep apnea (OSA) patients in North America. This partnership aims to leverage their technologies for improved patient screenings and treatments using Vivos' VivoScore product. Recent data shows that 56% of patients tested by Vivos dentists received positive OSA diagnoses, with 50% entering treatment. The collaboration seeks to increase access to personalized telemedicine care, addressing the needs of patients intolerant to traditional CPAP devices.

Vivos Therapeutics has received FDA 510(k) market clearance for its mmRNA device, a non-invasive treatment for mild to moderate obstructive sleep apnea (OSA). This approval increases the potential for insurance reimbursement, including Medicare. With over 54 million Americans affected by sleep apnea, Vivos aims to provide a cost-effective alternative to current treatments. The company also plans to appeal the FDA's denial of its DNA appliance application, although this is not expected to impact existing operations significantly.